home / stock / rptx / rptx quote
Last: | $3.89 |
---|---|
Change Percent: | -1.79% |
Open: | $3.97 |
Close: | $3.89 |
High: | $4.18 |
Low: | $3.76 |
Volume: | 68,469 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.89 | $3.97 | $3.89 | $4.18 | $3.76 | 68,469 | 07-22-2024 |
$3.9 | $4 | $3.9 | $4.29 | $3.9 | 185,466 | 07-19-2024 |
$3.94 | $3.69 | $3.94 | $4.1 | $3.62 | 323,061 | 07-18-2024 |
$3.68 | $3.8 | $3.68 | $4.02 | $3.68 | 139,864 | 07-17-2024 |
$3.85 | $3.62 | $3.85 | $4 | $3.62 | 235,252 | 07-16-2024 |
$3.6 | $3.49 | $3.6 | $3.73 | $3.44 | 326,315 | 07-15-2024 |
$3.48 | $3.57 | $3.48 | $3.66 | $3.4 | 232,394 | 07-12-2024 |
$3.55 | $3.51 | $3.55 | $3.8 | $3.47 | 250,390 | 07-11-2024 |
$3.45 | $3.42 | $3.45 | $3.54 | $3.3754 | 57,738 | 07-10-2024 |
$3.39 | $3.22 | $3.39 | $3.48 | $3.21 | 66,158 | 07-09-2024 |
$3.21 | $3.19 | $3.21 | $3.3 | $3.13 | 57,718 | 07-08-2024 |
$3.17 | $3.18 | $3.17 | $3.18 | $3.09 | 47,961 | 07-05-2024 |
$3.18 | $3.26 | $3.18 | $3.26 | $3.14 | 62,141 | 07-04-2024 |
$3.18 | $3.26 | $3.18 | $3.26 | $3.14 | 62,141 | 07-03-2024 |
$3.24 | $3.31 | $3.24 | $3.33 | $3.2 | 93,206 | 07-02-2024 |
$3.33 | $3.3 | $3.33 | $3.4 | $3.245 | 69,412 | 07-01-2024 |
$3.3 | $3.4 | $3.3 | $3.407 | $3.27 | 118,104 | 06-28-2024 |
$3.38 | $3.36 | $3.38 | $3.6088 | $3.26 | 170,451 | 06-27-2024 |
$3.37 | $3.38 | $3.37 | $3.47 | $3.26 | 622,217 | 06-26-2024 |
$3.41 | $3.53 | $3.41 | $3.54 | $3.32 | 87,671 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Repare Therapeutics Inc. Company Name:
RPTX Stock Symbol:
NASDAQ Market:
Repare Therapeutics Inc. Website:
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Canada NewsWire AEC invests US$7.5M into Amplitude Ventures US$192M Fund II to support the growth of life science startups, establishing a full-time Amplitude presence in ...
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine mon...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of th...